Plantar Fasciitis Treatment Market Size, Share & Trends Analysis Report By Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids), By Disease Type, By End Use, By Region, And Segment Forecasts, 2025 - 2033
Description
Plantar Fasciitis Treatment Market Summary
The global plantar fasciitis treatment market size was estimated at USD 1.28 billion in 2024 and is projected to reach USD 3.45 billion by 2033, growing at a CAGR of 11.9% from 2025 to 2033. The market growth is driven by rising prevalence of obesity, an aging population, and an increase in heel and foot strain cases caused by prolonged standing or high-impact activities.
Increasing awareness among patients about foot health, better access to specialized care, and the adoption of advanced treatment options are further supporting market expansion. Hospitals, clinics, and outpatient facilities are emphasizing early diagnosis and effective management of foot-related conditions. Combined, these factors are fueling demand for therapeutic interventions, driving consistent growth and encouraging innovation within the heel and foot care segment.
Although governments rarely provide exact global case figures, estimates suggest that approximately 1 million patient visits yearly are due to plantar fasciitis. Research indicates that around 10% of the population experience plantar fasciitis at some point, with 83% of affected individuals being active working adults aged 25 to 65. Some studies report prevalence rates as high as 22% among runners.
Developments in image-guided interventions, ultrasound-guided injections, and minimally invasive mechanical or sonic therapies improve targeting, reduce recovery time, and enhance efficacy, thus increasing physician and patient adoption. In July 2025, a study published in the American Journal of Physical Medicine & Rehabilitation compared the efficacy of platelet-rich plasma (PRP) and corticosteroids in treating plantar fasciitis. The results indicated that PRP provided superior pain relief and improved foot function over corticosteroid injections. In addition, in July 2025, a study by King George's Medical University researchers in Lucknow explored the effectiveness of ultrasound-guided dextrose prolotherapy versus PRP injections for chronic heel pain. The study found that both treatments significantly reduced pain and improved foot function, with PRP demonstrating slightly superior outcomes.
Global Plantar Fasciitis Treatment Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global plantar fasciitis treatment market report based on drug class, disease type, end use, and region:
The global plantar fasciitis treatment market size was estimated at USD 1.28 billion in 2024 and is projected to reach USD 3.45 billion by 2033, growing at a CAGR of 11.9% from 2025 to 2033. The market growth is driven by rising prevalence of obesity, an aging population, and an increase in heel and foot strain cases caused by prolonged standing or high-impact activities.
Increasing awareness among patients about foot health, better access to specialized care, and the adoption of advanced treatment options are further supporting market expansion. Hospitals, clinics, and outpatient facilities are emphasizing early diagnosis and effective management of foot-related conditions. Combined, these factors are fueling demand for therapeutic interventions, driving consistent growth and encouraging innovation within the heel and foot care segment.
Although governments rarely provide exact global case figures, estimates suggest that approximately 1 million patient visits yearly are due to plantar fasciitis. Research indicates that around 10% of the population experience plantar fasciitis at some point, with 83% of affected individuals being active working adults aged 25 to 65. Some studies report prevalence rates as high as 22% among runners.
Developments in image-guided interventions, ultrasound-guided injections, and minimally invasive mechanical or sonic therapies improve targeting, reduce recovery time, and enhance efficacy, thus increasing physician and patient adoption. In July 2025, a study published in the American Journal of Physical Medicine & Rehabilitation compared the efficacy of platelet-rich plasma (PRP) and corticosteroids in treating plantar fasciitis. The results indicated that PRP provided superior pain relief and improved foot function over corticosteroid injections. In addition, in July 2025, a study by King George's Medical University researchers in Lucknow explored the effectiveness of ultrasound-guided dextrose prolotherapy versus PRP injections for chronic heel pain. The study found that both treatments significantly reduced pain and improved foot function, with PRP demonstrating slightly superior outcomes.
Global Plantar Fasciitis Treatment Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global plantar fasciitis treatment market report based on drug class, disease type, end use, and region:
- Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Corticosteroids
- Others
- Disease Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Acute Plantar Fasciitis
- Chronic Plantar Fasciitis
- Others
- End Use Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Others
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Disease Type
- 1.2.3. End Use
- 1.2.4. Region
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Plantar Fasciitis Treatment Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- Chapter 4. Plantar Fasciitis Treatment Market: Drug Class Business Analysis
- 4.1. Drug Class Market Share, 2024 & 2033
- 4.2. Drug Class Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
- 4.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 4.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
- 4.5. Corticosteroids
- 4.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
- 4.6. Others
- 4.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
- Chapter 5. Plantar Fasciitis Treatment Market: Disease Type Business Analysis
- 5.1. Disease Type Market Share, 2024 & 2033
- 5.2. Disease Type Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Billion)
- 5.4. Acute Plantar Fasciitis
- 5.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
- 5.5. Chronic Plantar Fasciitis
- 5.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
- 5.6. Others
- 5.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
- Chapter 6. Plantar Fasciitis Treatment Market: End Use Business Analysis
- 6.1. End Use Market Share, 2024 & 2033
- 6.2. End Use Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
- 6.4. Hospitals & Clinics
- 6.4.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
- 6.5. Ambulatory Surgical Centers
- 6.5.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
- 6.6. Others
- 6.6.1. Market Estimates & Forecasts, 2021 - 2033 (USD Billion)
- Chapter 7. Plantar Fasciitis Treatment Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
- 7.4. North America
- 7.4.1. North America Plantar Fasciitis Treatment Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Billion)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Reimbursement Framework
- 7.4.2.5. U.S. Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Reimbursement Framework
- 7.4.3.5. Canada Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Reimbursement Framework
- 7.4.4.5. Mexico Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5. Europe
- 7.5.1. Europe Plantar Fasciitis Treatment Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Billion)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement Framework
- 7.5.2.5. UK Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement Framework
- 7.5.4.5. France Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Target Disease Prevalence
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Reimbursement Framework
- 7.5.5.5. Italy Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Target Disease Prevalence
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Reimbursement Framework
- 7.5.6.5. Spain Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Target Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Target Disease Prevalence
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement Framework
- 7.5.8.5. Sweden Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Target Disease Prevalence
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement Framework
- 7.5.9.5. Norway Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Plantar Fasciitis Treatment Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Billion)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement Framework
- 7.6.2.5. Japan Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement Framework
- 7.6.3.5. China Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement Framework
- 7.6.4.5. India Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement Framework
- 7.6.5.5. Australia Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Target Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Target Disease Prevalence
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement Framework
- 7.6.7.5. Thailand Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7. Latin America
- 7.7.1. Latin America Plantar Fasciitis Treatment Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Billion)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Target Disease Prevalence
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement Framework
- 7.7.2.5. Brazil Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Target Disease Prevalence
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement Framework
- 7.7.3.5. Argentina Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Plantar Fasciitis Treatment Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Billion)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Target Disease Prevalence
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Target Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Target Disease Prevalence
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement Framework
- 7.8.4.5. UAE Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Target Disease Prevalence
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement Framework
- 7.8.5.5. Kuwait Plantar Fasciitis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Pfizer Inc.
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Bayer AG
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Johnson & Johnson
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Viatris Inc.
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Teva Pharmaceutical Industries Ltd.
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Sanofi
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. AbbVie Inc.
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. GSK plc.
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Novartis AG
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Sun Pharmaceutical Industries Ltd.
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
